Endocrine manifestations of renal tumors; current knowledge
Open Access
- 6 February 2025
- journal article
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 14 (3) , e27588
Abstract
Renal cell carcinoma (RCC) can lead to various paraneoplastic syndromes, both endocrine and non-endocrine. Endocrine manifestations include hypercalcemia, hypertension, polycythemia, galactorrhea, Cushing’s syndrome, and alterations in glucose metabolism. These syndromes are not necessarily indicative of metastatic disease or poor prognosis but can present as paraneoplastic manifestations of primary or recurrent RCC. Understanding these manifestations is crucial for diagnosis and treatment, as they may be the initial signs of the disease.Keywords
This publication has 19 references indexed in Scilit:
- Polycythemia with Renal Cell Carcinoma and Normal Erythropoietin LevelCase Reports in Urology, 2019
- Cancer in Transgender People: Evidence and Methodological ConsiderationsEpidemiologic Reviews, 2017
- Insulin-like growth factor-1 signaling in renal cell carcinomaBMC Cancer, 2016
- Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomyWorld Journal of Urology, 2016
- Feminization and masculinization of western mosquitofish (Gambusia affinis) observed in rivers impacted by municipal wastewatersScientific Reports, 2016
- Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based studyWorld Journal of Urology, 2016
- Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial CarcinomaClinical Genitourinary Cancer, 2015
- Renal cell carcinoma: histological classification and correlation with imaging findingsRadiologia Brasileira, 2015
- Nephron-sparing surgery for treatment of reninoma: a rare renin secreting tumor causing secondary hypertensionInternational braz j urol, 2015
- Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted TherapiesThe Oncologist, 2010